Pharmacological approaches to retinitis pigmentosa: A laboratory perspective

Progress in Retinal and Eye Research

Volumn 48, Issue , 2015, Pages 62-81

  Guadagni, Viviana ^a   Novelli, Elena ^a   Piano, Ilaria ^b   Gargini, Claudia ^b   Strettoi, Enrica ^a  

^a CNR   (Italy)

^b UNIVERSITY OF PISA   (Italy)

Author keywords

Apoptosis; Ceramide; Environmental enrichment; Inflammation; Microglia; Neurotrophic factors; Orphan disease; Photoreceptors; Rare disease

Indexed keywords

9 CIS RETINOL ACETATE; ANTIOXIDANT; CILIARY NEUROTROPHIC FACTOR; DOCOSAHEXAENOIC ACID; RETINOL; ROD DERIVED CONE VIABILITY FACTOR; SPHINGOLIPID; VALPROIC ACID; NERVE GROWTH FACTOR; NEUROPROTECTIVE AGENT; NXNL1 PROTEIN, HUMAN; THIOREDOXIN;

ARTICLE; CELL DEATH; CLINICAL TRIAL (TOPIC); ENDOPROSTHESIS; HUMAN; LABORATORY; NEUROPROTECTION; NONHUMAN; OPTOGENETICS; PHOTORECEPTOR; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINITIS PIGMENTOSA; SIGNAL TRANSDUCTION; ANIMAL; DISEASE MODEL;

ANIMALS; CILIARY NEUROTROPHIC FACTOR; DISEASE MODELS, ANIMAL; HUMANS; NERVE GROWTH FACTORS; NEUROPROTECTIVE AGENTS; RETINITIS PIGMENTOSA; THIOREDOXINS;

EID: 84939264496     PISSN: 13509462     EISSN: 18731635     Source Type: Journal    
DOI: 10.1016/j.preteyeres.2015.06.005     Document Type: Article

References (187)

1. Acharya U., Acharya J.K. Enzymes of sphingolipid metabolism in Drosophila melanogaster. Cell. Mol. Life Sci. 2005, 62:128-142.
2. Acharya U., Patel S., Koundakjian E., Nagashima K., Han X., Acharya J.K. Modulating sphingolipid biosynthetic pathway rescues photoreceptor degeneration. Science 2003, 299:1740-1743.
3. Akiyama M., Ikeda Y., Yoshida N., Notomi S., Murakami Y., Hisatomi T., Enaida H., Ishibashi T. Therapeutic efficacy of topical unoprostone isopropyl in retinitis pigmentosa. Acta Ophthalmol. 2014, 92:e229-234.
4. Arango-Gonzalez B., Trifunovic D., Sahaboglu A., Kranz K., Michalakis S., Farinelli P., Koch S., Koch F., Cottet S., Janssen-Bienhold U., Dedek K., Biel M., Zrenner E., Euler T., Ekstrom P., Ueffing M., Paquet-Durand F. Identification of a common non-apoptotic cell death mechanism in hereditary retinal degeneration. PLoS One 2014, 9:e112142.
5. Arroba A.I., Alvarez-Lindo N., van Rooijen N., de la Rosa E.J. Microglia-mediated IGF-I neuroprotection in the rd10 Mouse Model of retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 2011, 52:9124-9130.
6. Auslender N., Sharon D., Abbasi A.H., Garzozi H.J., Banin E., Ben-Yosef T. Acommon founder mutation of CERKL underlies autosomal recessive retinal degeneration with early macular involvement among Yemenite Jews. Investig. Ophthalmol. Vis. Sci. 2007, 48:5431-5438.
7. Bainbridge J.W., Mehat M.S., Sundaram V., Robbie S.J., Barker S.E., Ripamonti C., Georgiadis A., Mowat F.M., Beattie S.G., Gardner P.J., Feathers K.L., Luong V.A., Yzer S., Balaggan K., Viswanathan A., de Ravel T.J., Casteels I., Holder G.E., Tyler N., Fitzke F.W., Weleber R.G., Nardini M., Moore A.T., Thompson D.A., Petersen-Jones S.M., Michaelides M., van den Born L.I., Stockman A., Smith A.J., Rubin G., Ali R.R. Long-term effect of gene therapy on Leber's congenital amaurosis. N.Engl. J. Med. 2015, 372:1887-1897.
8. Bainbridge J.W., Smith A.J., Barker S.S., Robbie S., Henderson R., Balaggan K., Viswanathan A., Holder G.E., Stockman A., Tyler N., Petersen-Jones S., Bhattacharya S.S., Thrasher A.J., Fitzke F.W., Carter B.J., Rubin G.S., Moore A.T., Ali R.R. Effect of gene therapy on visual function in Leber's congenital amaurosis. N.Engl. J. Med. 2008, 358:2231-2239.
9. Bandhuvula P., Honbo N., Wang G.Y., Jin Z.Q., Fyrst H., Zhang M., Borowsky A.D., Dillard L., Karliner J.S., Saba J.D. S1P lyase: a novel therapeutic target for ischemia-reperfusion injury of the heart. Am. J. Physiol. Heart Circ. Physiol. 2011, 300:H1753-H1761.
10. Barnard A.R., Groppe M., MacLaren R.E. Gene therapy for choroideremia using an adeno-associated viral (AAV) vector. Cold Spring Harb. Perspect. Med. 2014, 5.
11. Baroncelli L., Bonaccorsi J., Milanese M., Bonifacino T., Giribaldi F., Manno I., Cenni M.C., Berardi N., Bonanno G., Maffei L., Sale A. Enriched experience and recovery from amblyopia in adult rats: impact of motor, social and sensory components. Neuropharmacology 2012, 62:2388-2397.
12. Baroncelli L., Braschi C., Spolidoro M., Begenisic T., Sale A., Maffei L. Nurturing brain plasticity: impact of environmental enrichment. Cell Death Differ. 2010, 17:1092-1103.
13. Barone I., Novelli E., Piano I., Gargini C., Strettoi E. Environmental enrichment extends photoreceptor survival and visual function in a mouse model of retinitis pigmentosa. PLoS One 2012, 7:e50726.
14. Barone I., Novelli E., Strettoi E. Long-term preservation of cone photoreceptors and visual acuity in rd10 mutant mice exposed to continuous environmental enrichment. Mol. Vis. 2014, 20:1545-1556.
15. Bello V., Mattei G., Mazzoldi P., Vivenza N., Gasco P., Idee J.M., Robic C., Borsella E. Transmission electron microscopy of lipid vesicles for drug delivery: comparison between positive and negative staining. Microsc. Microanal. 2010, 16:456-461.
16. Berson E.L. Nutrition and retinal degenerations. Vitamin A, taurine, ornithine, and phytanic acid. Retina 1982, 2:236-255.
17. Berson E.L., Rosner B., Sandberg M.A., Hayes K.C., Nicholson B.W., Weigel-DiFrano C., Willett W. Vitamin A supplementation for retinitis pigmentosa. Arch. Ophthalmol. 1993, 111:1456-1459.
18. Berson E.L., Rosner B., Sandberg M.A., Weigel-DiFranco C., Brockhurst R.J., Hayes K.C., Johnson E.J., Anderson E.J., Johnson C.A., Gaudio A.R., Willett W.C., Schaefer E.J. Clinical trial of lutein in patients with retinitis pigmentosa receiving vitamin A. Arch. Ophthalmol. 2010, 128:403-411.
19. Berson E.L., Rosner B., Sandberg M.A., Weigel-DiFranco C., Willett W.C. omega-3 intake and visual acuity in patients with retinitis pigmentosa receiving vitamin A. Arch. Ophthalmol. 2012, 130:707-711.
20. Bhalla S., Joshi D., Bhullar S., Kasuga D., Park Y., Kay C.N. Long-term follow-up for efficacy and safety of treatment of retinitis pigmentosa with valproic acid. Br. J. Ophthalmol. 2013, 97:895-899.
21. Birch D.G., Weleber R.G., Duncan J.L., Jaffe G.J., Tao W. Randomized trial of ciliary neurotrophic factor delivered by encapsulated cell intraocular implants for retinitis pigmentosa. Am. J. Ophthalmol. 2013, 156. 283-292 e281.
22. Boye S.E., Boye S.L., Lewin A.S., Hauswirth W.W. Acomprehensive review of retinal gene therapy. Mol. Ther. 2013, 21:509-519.
23. Brown I., Cascio M.G., Rotondo D., Pertwee R.G., Heys S.D., Wahle K.W. Cannabinoids and omega-3/6 endocannabinoids as cell death and anticancer modulators. Prog. Lipid Res. 2013, 52:80-109.
24. Buchhold B., Mogoanta L., Suofu Y., Hamm A., Walker L., Kessler C., Popa-Wagner A. Environmental enrichment improves functional and neuropathological indices following stroke in young and aged rats. Restor. Neurol. Neurosci. 2007, 25:467-484.
25. Budzynski E., Gross A.K., McAlear S.D., Peachey N.S., Shukla M., He F., Edwards M., Won J., Hicks W.L., Wensel T.G., Naggert J.K., Nishina P.M. Mutations of the opsin gene (Y102H and I307N) lead to light-induced degeneration of photoreceptors and constitutive activation of phototransduction in mice. J.Biol. Chem. 2010, 285:14521-14533.
26. Canals D., Hannun Y.A. Novel chemotherapeutic drugs in sphingolipid cancer research. Handb. Exp. Pharmacol. 2013, 211-238.
27. Caretti A., Bragonzi A., Facchini M., De Fino I., Riva C., Gasco P., Musicanti C., Casas J., Fabrias G., Ghidoni R., Signorelli P. Anti-inflammatory action of lipid nanocarrier-delivered myriocin: therapeutic potential in cystic fibrosis. Biochim. Biophys. Acta 2014, 1840:586-594.
28. Casson R.J., Chidlow G., Ebneter A., Wood J.P., Crowston J., Goldberg I. Translational neuroprotection research in glaucoma: a review of definitions and principles. Clin. Exp. Ophthalmol. 2012, 40:350-357.
29. Cepko C.L. Emerging gene therapies for retinal degenerations. J.Neurosci. 2012, 32:6415-6420.
30. Chader G.J. Animal models in research on retinal degenerations: past progress and future hope. Vis. Res. 2002, 42:393-399.
31. Chen H., Tran J.T., Brush R.S., Saadi A., Rahman A.K., Yu M., Yasumura D., Matthes M.T., Ahern K., Yang H., LaVail M.M., Mandal M.N. Ceramide signaling in retinal degeneration. Adv. Exp. Med. Biol. 2012, 723:553-558.
32. Cideciyan A.V., Jacobson S.G., Beltran W.A., Sumaroka A., Swider M., Iwabe S., Roman A.J., Olivares M.B., Schwartz S.B., Komaromy A.M., Hauswirth W.W., Aguirre G.D. Human retinal gene therapy for Leber congenital amaurosis shows advancing retinal degeneration despite enduring visual improvement. Proc. Natl. Acad. Sci. U. S. A. 2013, 110:E517-E525.
33. Cima M.J., Lee H., Daniel K., Tanenbaum L.M., Mantzavinou A., Spencer K.C., Ong Q., Sy J.C., Santini J., Schoellhammer C.M., Blankschtein D., Langer R.S. Single compartment drug delivery. J.Control Release 2014, 190:157-171.
34. Cincarova L., Zdrahal Z., Fajkus J. New perspectives of valproic acid in clinical practice. Expert Opin. Investig. Drugs 2013, 22:1535-1547.
35. Cingolani C., Rogers B., Lu L., Kachi S., Shen J., Campochiaro P.A. Retinal degeneration from oxidative damage. Free Radic. Biol. Med. 2006, 40:660-669.
36. Clarke G., Collins R.A., Leavitt B.R., Andrews D.F., Hayden M.R., Lumsden C.J., McInnes R.R. Aone-hit model of cell death in inherited neuronal degenerations. Nature 2000, 406:195-199.
37. Clemson C.M., Tzekov R., Krebs M., Checchi J.M., Bigelow C., Kaushal S. Therapeutic potential of valproic acid for retinitis pigmentosa. Br. J. Ophthalmol. 2011, 95:89-93.
38. Cottet S., Schorderet D.F. Mechanisms of apoptosis in retinitis pigmentosa. Curr. Mol. Med. 2009, 9:375-383.
39. Cronin T., Raffelsberger W., Lee-Rivera I., Jaillard C., Niepon M.L., Kinzel B., Clerin E., Petrosian A., Picaud S., Poch O., Sahel J.A., Leveillard T. The disruption of the rod-derived cone viability gene leads to photoreceptor dysfunction and susceptibility to oxidative stress. Cell Death Differ. 2010, 17:1199-1210.
40. Cuenca N., Fernandez-Sanchez L., Campello L., Maneu V., De la Villa P., Lax P., Pinilla I. Cellular responses following retinal injuries and therapeutic approaches for neurodegenerative diseases. Prog. Retin. Eye Res. 2014, 43:17-75.
41. Daiger S.P., Sullivan L.S., Bowne S.J. Genes and mutations causing retinitis pigmentosa. Clin. Genet. 2013, 84:132-141.
42. Dalkara D., Duebel J., Sahel J.A. Gene therapy for the eye focus on mutation-independent approaches. Curr. Opin. Neurol. 2015, 28:51-60.
43. Delyfer M.N., Leveillard T., Mohand-Said S., Hicks D., Picaud S., Sahel J.A. Inherited retinal degenerations: therapeutic prospects. Biol. Cell 2004, 96:261-269.
44. den Hollander A.I., Roepman R., Koenekoop R.K., Cremers F.P. Leber congenital amaurosis: genes, proteins and disease mechanisms. Prog. Retin. Eye Res. 2008, 27:391-419.
45. Elachouri G., Lee-Rivera I., Clerin E., Argentini M., Fridlich R., Blond F., Ferracane V., Yang Y., Raffelsberger W., Wan J., Bennett J., Sahel J.A., Zack D.J., Leveillard T. Thioredoxin rod-derived cone viability factor protects against photooxidative retinal damage. Free Radic. Biol. Med. 2015, 81:22-29.
46. Emerich D.F., Thanos C.G. NT-501: an ophthalmic implant of polymer-encapsulated ciliary neurotrophic factor-producing cells. Curr. Opin. Mol. Ther. 2008, 10:506-515.
47. Eversole-Cire P., Concepcion F.A., Simon M.I., Takayama S., Reed J.C., Chen J. Synergistic effect of Bcl-2 and BAG-1 on the prevention of photoreceptor cell death. Investig. Ophthalmol. Vis. Sci. 2000, 41:1953-1961.
48. Fahim A.T., Bowne S.J., Sullivan L.S., Webb K.D., Williams J.T., Wheaton D.K., Birch D.G., Daiger S.P. Allelic heterogeneity and genetic modifier loci contribute to clinical variation in males with X-linked retinitis pigmentosa due to RPGR mutations. PLoS One 2011, 6:e23021.
49. Ferrari M.P., Mantelli F., Sacchetti M., Antonangeli M.I., Cattani F., D'Anniballe G., Sinigaglia F., Ruffini P.A., Lambiase A. Safety and pharmacokinetics of escalating doses of human recombinant nerve growth factor eye drops in a double-masked, randomized clinical trial. BioDrugs 2014, 28:275-283.
50. Ferrari S., Di Iorio E., Barbaro V., Ponzin D., Sorrentino F.S., Parmeggiani F. Retinitis pigmentosa: genes and disease mechanisms. Curr. Genomics 2011, 12:238-249.
51. Finkel T. Oxidant signals and oxidative stress. Curr. Opin. Cell Biol. 2003, 15:247-254.
52. Fortin D.L., Banghart M.R., Dunn T.W., Borges K., Wagenaar D.A., Gaudry Q., Karakossian M.H., Otis T.S., Kristan W.B., Trauner D., Kramer R.H. Photochemical control of endogenous ion channels and cellular excitability. Nat. Methods 2008, 5:331-338.
53. Franklin T.B., Murphy J.A., Myers T.L., Clarke D.B., Currie R.W. Enriched environment during adolescence changes brain-derived neurotrophic factor and TrkB levels in the rat visual system but does not offer neuroprotection to retinal ganglion cells following axotomy. Brain Res. 2006, 1095:1-11.
54. Fu L., Lo A.C.Y., Lai J.S.M., Shih K.C. The role of electrical stimulation therapy in ophthalmic diseases. Graefes Arch. Clin. Exp. 2015, 253:171-176.
55. Gasco M.R., Gasco P. Nanovector. Nanomedicine (Lond.) 2007, 2:955-960.
56. Gasco M.R., Priano L., Zara G.P. Chapter 10-Solid lipid nanoparticles and microemulsions for drug delivery the CNS. Prog. Brain Res. 2009, 180:181-192.
57. German O.L., Miranda G.E., Abrahan C.E., Rotstein N.P. Ceramide is a mediator of apoptosis in retina photoreceptors. Investig. Ophthalmol. Vis. Sci. 2006, 47:1658-1668.
58. Gomez-Pinilla F., Vaynman S., Ying Z. Brain-derived neurotrophic factor functions as a metabotrophin to mediate the effects of exercise on cognition. Eur. J. Neurosci. 2008, 28:2278-2287.
59. Gorshkova I.A., Wang H., Orbelyan G.A., Goya J., Natarajan V., Beiser D.G., Vanden Hoek T.L., Berdyshev E.V. Inhibition of sphingosine-1-phosphate lyase rescues sphingosine kinase-1-knockout phenotype following murine cardiac arrest. Life Sci. 2013, 93:359-366.
60. Grazide S., Maestre N., Veldman R.J., Bezombes C., Maddens S., Levade T., Laurent G., Jaffrezou J.P. Ara-C- and daunorubicin-induced recruitment of Lyn in sphingomyelinase-enriched membrane rafts. FASEB J. 2002, 16:1685-1687.
61. Hamel C.P. Cone rod dystrophies. Orphanet J. Rare Dis. 2007, 2:7.
62. Hannun Y.A., Obeid L.M. Principles of bioactive lipid signalling: lessons from sphingolipids. Nat. Rev. Mol. Cell Biol. 2008, 9:139-150.
63. Hartong D.T., Berson E.L., Dryja T.P. Retinitis pigmentosa. Lancet 2006, 368:1795-1809.
64. Haughey N.J., Bandaru V.V., Bae M., Mattson M.P. Roles for dysfunctional sphingolipid metabolism in Alzheimer's disease neuropathogenesis. Biochim. Biophys. Acta 2010, 1801:878-886.
65. Heckenlively J.R., Aptsiauri N., Nusinowitz S., Peng C., Hargrave P.A. Investigations of antiretinal antibodies in pigmentary retinopathy and other retinal degenerations. Trans. Am. Ophthalmol. Soc. 1996, 94:179-200. discussion 200-176.
66. Heckenlively J.R., Jordan B.L., Aptsiauri N. Association of antiretinal antibodies and cystoid macular edema in patients with retinitis pigmentosa. Am. J. Ophthalmol. 1999, 127:565-573.
67. Herrero-Vanrell R., Bravo-Osuna I., Andres-Guerrero V., Vicario-de-la-Torre M., Molina-Martinez I.T. The potential of using biodegradable microspheres in retinal diseases and other intraocular pathologies. Prog. Retin. Eye Res. 2014, 42:27-43.
68. Herring A., Yasin H., Ambree O., Sachser N., Paulus W., Keyvani K. Environmental enrichment counteracts Alzheimer's neurovascular dysfunction in TgCRND8 mice. Brain Pathol. 2008, 18:32-39.
69. Hoffman D.R., Hughbanks-Wheaton D.K., Pearson N.S., Fish G.E., Spencer R., Takacs A., Klein M., Locke K.G., Birch D.G. Four-year placebo-controlled trial of docosahexaenoic acid in X-linked retinitis pigmentosa (DHAX trial): a randomized clinical trial. JAMA Ophthalmol. 2014, 132:866-873.
70. Hughbanks-Wheaton D.K., Birch D.G., Fish G.E., Spencer R., Pearson N.S., Takacs A., Hoffman D.R. Safety assessment of docosahexaenoic acid in X-linked retinitis pigmentosa: the 4-year DHAX trial. Investig. Ophthalmol. Vis. Sci. 2014, 55:4958-4966.
71. Iezzi R., Guru B.R., Glybina I.V., Mishra M.K., Kennedy A., Kannan R.M. Dendrimer-based targeted intravitreal therapy for sustained attenuation of neuroinflammation in retinal degeneration. Biomaterials 2012, 33:979-988.
72. Ito D., Imai Y., Ohsawa K., Nakajima K., Fukuuchi Y., Kohsaka S. Microglia-specific localisation of a novel calcium binding protein, Iba1. Brain Res. Mol. Brain Res. 1998, 57:1-9.
73. Jeffrey B.G., Weisinger H.S., Neuringer M., Mitchell D.C. The role of docosahexaenoic acid in retinal function. Lipids 2001, 36:859-871.
74. Kauper K., McGovern C., Sherman S., Heatherton P., Rapoza R., Stabila P., Dean B., Lee A., Borges S., Bouchard B., Tao W. Two-year intraocular delivery of ciliary neurotrophic factor by encapsulated cell technology implants in patients with chronic retinal degenerative diseases. Investig. Ophthalmol. Vis. Sci. 2012, 53:7484-7491.
75. Kim H.J., Rowe M., Ren M., Hong J.S., Chen P.S., Chuang D.M. Histone deacetylase inhibitors exhibit anti-inflammatory and neuroprotective effects in a rat permanent ischemic model of stroke: multiple mechanisms of action. J.Pharmacol. Exp. Ther. 2007, 321:892-901.
76. Kitiratschky V.B.D., Stingl K., Wilhelm B., Peters T., Besch D., Sachs H., Gekeler F., Bartz-Schmidt K.U., Zrenner E. Safety evaluation of "retina implant alpha IMS aEuro" a prospective clinical trial. Graefes Arch. Clin. Exp. 2015, 253:381-387.
77. Koenekoop R.K., Sui R., Sallum J., van den Born L.I., Ajlan R., Khan A., den Hollander A.I., Cremers F.P., Mendola J.D., Bittner A.K., Dagnelie G., Schuchard R.A., Saperstein D.A. Oral 9-cis retinoid for childhood blindness due to Leber congenital amaurosis caused by RPE65 or LRAT mutations: an open-label phase 1b trial. Lancet 2014, 384:1513-1520.
78. Kohno H., Chen Y., Kevany B.M., Pearlman E., Miyagi M., Maeda T., Palczewski K., Maeda A. Photoreceptor proteins initiate microglial activation via Toll-like receptor 4 in retinal degeneration mediated by all-trans-retinal. J.Biol. Chem. 2013, 288:15326-15341.
79. Kohno H., Maeda T., Perusek L., Pearlman E., Maeda A. CCL3 production by microglial cells modulates disease severity in murine models of retinal degeneration. J.Immunol. 2014, 192:3816-3827.
80. Komeima K., Rogers B.S., Campochiaro P.A. Antioxidants slow photoreceptor cell death in mouse models of retinitis pigmentosa. J.Cell. Physiol. 2007, 213:809-815.
81. Komeima K., Rogers B.S., Lu L., Campochiaro P.A. Antioxidants reduce cone cell death in a model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 2006, 103:11300-11305.
82. Komeima K., Usui S., Shen J., Rogers B.S., Campochiaro P.A. Blockade of neuronal nitric oxide synthase reduces cone cell death in a model of retinitis pigmentosa. Free Radic. Biol. Med. 2008, 45:905-912.
83. Kornhuber J., Reichel M., Tripal P., Groemer T.W., Henkel A.W., Muhle C., Gulbins E. The role of ceramide in major depressive disorder. Eur. Arch. Psychiatry Clin. Neurosci. 2009, 259(Suppl.2):S199-S204.
84. Kumar A., Midha N., Gogia V., Gupta S., Sehra S., Chohan A. Efficacy of oral valproic acid in patients with retinitis pigmentosa. J.Ocul. Pharmacol. Ther. 2014, 30:580-586.
85. Kumar M., Gupta R.M., Nema H.V. Role of autoimmunity in retinitis pigmentosa. Ann. Ophthalmol. 1983, 15:838-840.
86. Lai A.Y., Todd K.G. Differential regulation of trophic and proinflammatory microglial effectors is dependent on severity of neuronal injury. Glia 2008, 56:259-270.
87. Lambiase A., Aloe L., Centofanti M., Parisi V., Mantelli F., Colafrancesco V., Manni G.L., Bucci M.G., Bonini S., Levi-Montalcini R. Experimental and clinical evidence of neuroprotection by nerve growth factor eye drops: Implications for glaucoma. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:13469-13474.
88. Lambiase A., Coassin M., Sposato V., Micera A., Sacchetti M., Bonini S., Aloe L. NGF topical application in patients with corneal ulcer does not generate circulating NGF antibodies. Pharmacol. Res. 2007, 56:65-69.
89. Lambiase A., Mantelli F., Sacchetti M., Rossi S., Aloe L., Bonini S. Clinical applications of NGF in ocular diseases. Arch. Ital. Biol. 2011, 149:283-292.
90. LaVail M.M., Yasumura D., Matthes M.T., Lau-Villacorta C., Unoki K., Sung C.H., Steinberg R.H. Protection of mouse photoreceptors by survival factors in retinal degenerations. Investig. Ophthalmol. Vis. Sci. 1998, 39:592-602.
91. Lawson E.C., Han M.K., Sellers J.T., Chrenek M.A., Hanif A., Gogniat M.A., Boatright J.H., Pardue M.T. Aerobic exercise protects retinal function and structure from light-induced retinal degeneration. J.Neurosci. 2014, 34:2406-2412.
92. Lee S.Y., Usui S., Zafar A.B., Oveson B.C., Jo Y.J., Lu L., Masoudi S., Campochiaro P.A. N-Acetylcysteine promotes long-term survival of cones in a model of retinitis pigmentosa. J.Cell. Physiol. 2011, 226:1843-1849.
93. Leveillard T., Mohand-Said S., Lorentz O., Hicks D., Fintz A.C., Clerin E., Simonutti M., Forster V., Cavusoglu N., Chalmel F., Dolle P., Poch O., Lambrou G., Sahel J.A. Identification and characterization of rod-derived cone viability factor. Nat. Genet. 2004, 36:755-759.
94. Leveillard T., Sahel J.A. Rod-derived cone viability factor for treating blinding diseases: from clinic to redox signaling. Sci. Transl. Med. 2010, 2. 26ps16.
95. Lu L., Oveson B.C., Jo Y.J., Lauer T.W., Usui S., Komeima K., Xie B., Campochiaro P.A. Increased expression of glutathione peroxidase 4 strongly protects retina from oxidative damage. Antioxid. Redox Signal. 2009, 11:715-724.
96. Luo Y.H., Zhong J.J., da Cruz L. The use of Argus(R) II retinal prosthesis by blind subjects to achieve localisation and prehension of objects in 3-dimensional space. Graefes Arch. Clin. Exp. Ophthalmol. 2014.
97. MacLaren R.E., Groppe M., Barnard A.R., Cottriall C.L., Tolmachova T., Seymour L., Clark K.R., During M.J., Cremers F.P., Black G.C., Lotery A.J., Downes S.M., Webster A.R., Seabra M.C. Retinal gene therapy in patients with choroideremia: initial findings from a phase 1/2 clinical trial. Lancet 2014, 383:1129-1137.
98. Maeda T., Cideciyan A.V., Maeda A., Golczak M., Aleman T.S., Jacobson S.G., Palczewski K. Loss of cone photoreceptors caused by chromophore depletion is partially prevented by the artificial chromophore pro-drug, 9-cis-retinyl acetate. Hum. Mol. Genet. 2009, 18:2277-2287.
99. Maeda T., Maeda A., Casadesus G., Palczewski K., Margaron P. Evaluation of 9-cis-retinyl acetate therapy in Rpe65-/- mice. Investig. Ophthalmol. Vis. Sci. 2009, 50:4368-4378.
100. Maeda T., Maeda A., Leahy P., Saperstein D.A., Palczewski K. Effects of long-term administration of 9-cis-retinyl acetate on visual function in mice. Investig. Ophthalmol. Vis. Sci. 2009, 50:322-333.
101. Maguire A.M., Simonelli F., Pierce E.A., Pugh E.N., Mingozzi F., Bennicelli J., Banfi S., Marshall K.A., Testa F., Surace E.M., Rossi S., Lyubarsky A., Arruda V.R., Konkle B., Stone E., Sun J., Jacobs J., Dell'Osso L., Hertle R., Ma J.X., Redmond T.M., Zhu X., Hauck B., Zelenaia O., Shindler K.S., Maguire M.G., Wright J.F., Volpe N.J., McDonnell J.W., Auricchio A., High K.A., Bennett J. Safety and efficacy of gene transfer for Leber's congenital amaurosis. N.Engl. J. Med. 2008, 358:2240-2248.
102. Marc R.E., Jones B.W., Watt C.B., Strettoi E. Neural remodeling in retinal degeneration. Prog. Retin. Eye Res. 2003, 22:607-655.
103. Marigo V. Programmed cell death in retinal degeneration: targeting apoptosis in photoreceptors as potential therapy for retinal degeneration. Cell Cycle 2007, 6:652-655.
104. Mendes H.F., Zaccarini R., Cheetham M.E. Pharmacological manipulation of rhodopsin retinitis pigmentosa. Adv. Exp. Med. Biol. 2010, 664:317-323.
105. Mielke M.M., Lyketsos C.G. Alterations of the sphingolipid pathway in Alzheimer's disease: new biomarkers and treatment targets?. Neuromolecular Med. 2010, 12:331-340.
106. Minelli R., Serpe L., Pettazzoni P., Minero V., Barrera G., Gigliotti C., Mesturini R., Rosa A., Gasco P., Vivenza N., Muntoni E., Fantozzi R., Dianzani U., Zara G., Dianzani C. Cholesteryl butyrate solid lipid nanoparticles inhibit the adhesion and migration of colon cancer cells. Br. J. Pharmacol. 2012, 166:587-601.
107. Mitton K.P., Guzman A.E., Deshpande M., Byrd D., DeLooff C., Mkoyan K., Zlojutro P., Wallace A., Metcalf B., Laux K., Sotzen J., Tran T. Different effects of valproic acid on photoreceptor loss in Rd1 and Rd10 retinal degeneration mice. Mol. Vis. 2014, 20:1527-1544.
108. Murakami Y., Notomi S., Hisatomi T., Nakazawa T., Ishibashi T., Miller J.W., Vavvas D.G. Photoreceptor cell death and rescue in retinal detachment and degenerations. Prog. Retin. Eye Res. 2013, 37:114-140.
109. Najafi M., Maza N.A., Calvert P.D. Steric volume exclusion sets soluble protein concentrations in photoreceptor sensory cilia. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:203-208.
110. Nithianantharajah J., Hannan A.J. The neurobiology of brain and cognitive reserve: mental and physical activity as modulators of brain disorders. Prog. Neurobiol. 2009, 89:369-382.
111. Otani A., Kojima H., Guo C., Oishi A., Yoshimura N. Low-dose-rate, low-dose irradiation delays neurodegeneration in a model of retinitis pigmentosa. Am. J. Pathol. 2012, 180:328-336.
112. Park P.S. Constitutively active rhodopsin and retinal disease. Adv. Pharmacol. 2014, 70:1-36.
113. Parmeggiani F., Sorrentino F.S., Romano M.R., Costagliola C., Semeraro F., Incorvaia C., D'Angelo S., Perri P., De Nadai K., Bonomo Roversi E., Franceschelli P., Sebastiani A., Rubini M. Mechanism of inflammation in age-related macular degeneration: an up-to-date on genetic landmarks. Mediat. Inflamm. 2013, 2013:435607.
114. Paskowitz D.M., LaVail M.M., Duncan J.L. Light and inherited retinal degeneration. Br. J. Ophthalmol. 2006, 90:1060-1066.
115. Pearce W., Hsu J., Yeh S. Advances in drug delivery to the posterior segment. Curr. Opin. Ophthalmol. 2015, 26:233-239.
116. Peng B., Xiao J., Wang K., So K.F., Tipoe G.L., Lin B. Suppression of microglial activation is neuroprotective in a mouse model of human retinitis pigmentosa. J.Neurosci. 2014, 34:8139-8150.
117. Pham T.M., Winblad B., Granholm A.C., Mohammed A.H. Environmental influences on brain neurotrophins in rats. Pharmacol. Biochem. Behav. 2002, 73:167-175.
118. Piano I., Novelli E., Gasco P., Ghidoni R., Strettoi E., Gargini C. Cone survival and preservation of visual acuity in an animal model of retinal degeneration. Eur. J. Neurosci. 2013, 37:1853-1862.
119. Pierce E.A., Bennett J. The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb. Perspect. Med. 2015.
120. Podbielska M., Krotkiewski H., Hogan E.L. Signaling and regulatory functions of bioactive sphingolipids as therapeutic targets in multiple sclerosis. Neurochem. Res. 2012, 37:1154-1169.
121. Polosukhina A., Litt J., Tochitsky I., Nemargut J., Sychev Y., De Kouchkovsky I., Huang T., Borges K., Trauner D., Van Gelder R.N., Kramer R.H. Photochemical restoration of visual responses in blind mice. Neuron 2012, 75:271-282.
122. Posse de Chaves E.I. Sphingolipids in apoptosis, survival and regeneration in the nervous system. Biochim. Biophys. Acta 2006, 1758:1995-2015.
123. Punzo C., Kornacker K., Cepko C.L. Stimulation of the insulin/mTOR pathway delays cone death in a mouse model of retinitis pigmentosa. Nat. Neurosci. 2009, 12:44-52.
124. Punzo C., Xiong W., Cepko C.L. Loss of daylight vision in retinal degeneration: are oxidative stress and metabolic dysregulation to blame?. J.Biol. Chem. 2012, 287:1642-1648.
125. Pyne N.J., Pyne S. Sphingosine 1-phosphate and cancer. Nat. Rev. Cancer 2010, 10:489-503.
126. Qi X., Sun L., Lewin A.S., Hauswirth W.W., Guy J. Long-term suppression of neurodegeneration in chronic experimental optic neuritis: antioxidant gene therapy. Investig. Ophthalmol. Vis. Sci. 2007, 48:5360-5370.
127. Rahi A.H., Addison D.J. Autoimmunity and the outer retina. Trans. Ophthalmol. Soc. U. K. 1983, 103(Pt 4):428-437.
128. Ratnapriya R., Swaroop A. Genetic architecture of retinal and macular degenerative diseases: the promise and challenges of next-generation sequencing. Genome Med. 2013, 5.
129. Rayapudi S., Schwartz S.G., Wang X., Chavis P. Vitamin A and fish oils for retinitis pigmentosa. Cochrane Database Syst. Rev. 2013, 12. CD008428.
130. Redolat R., Mesa-Gresa P. Potential benefits and limitations of enriched environments and cognitive activity on age-related behavioural decline. Curr. Top. Behav. Neurosci. 2012, 10:293-316.
131. Roesch K., Stadler M.B., Cepko C.L. Gene expression changes within Muller glial cells in retinitis pigmentosa. Mol. Vis. 2012, 18:1197-1214.
132. Rotstein N.P., Miranda G.E., Abrahan C.E., German O.L. Regulating survival and development in the retina: key roles for simple sphingolipids. J.Lipid Res. 2010, 51:1247-1262.
133. Saad A.F., Meacham W.D., Bai A., Anelli V., Elojeimy S., Mahdy A.E., Turner L.S., Cheng J., Bielawska A., Bielawski J., Keane T.E., Obeid L.M., Hannun Y.A., Norris J.S., Liu X. The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol. Ther. 2007, 6:1455-1460.
134. Sahel J., Bonnel S., Mrejen S., Paques M. Retinitis pigmentosa and other dystrophies. Dev. Ophthalmol. 2010, 47:160-167.
135. Sahel J.A., Roska B. Gene therapy for blindness. Annu. Rev. Neurosci. 2013, 36:467-488.
136. Sahni J.N., Angi M., Irigoyen C., Semeraro F., Romano M.R., Parmeggiani F. Therapeutic challenges to retinitis pigmentosa: from neuroprotection to gene therapy. Curr. Genomics 2011, 12:276-284.
137. Sale A., Berardi N., Maffei L. Environment and brain plasticity: towards an endogenous pharmacotherapy. Physiol. Rev. 2014, 94:189-234.
138. Sale A., Cenni M.C., Ciucci F., Putignano E., Chierzi S., Maffei L. Maternal enrichment during pregnancy accelerates retinal development of the fetus. PLoS One 2007, 2:e1160.
139. Sale A., Putignano E., Cancedda L., Landi S., Cirulli F., Berardi N., Maffei L. Enriched environment and acceleration of visual system development. Neuropharmacology 2004, 47:649-660.
140. Salvemini D., Doyle T., Kress M., Nicol G. Therapeutic targeting of the ceramide-to-sphingosine 1-phosphate pathway in pain. Trends Pharmacol. Sci. 2013, 34:110-118.
141. Sancho-Pelluz J., Arango-Gonzalez B., Kustermann S., Romero F.J., van Veen T., Zrenner E., Ekstrom P., Paquet-Durand F. Photoreceptor cell death mechanisms in inherited retinal degeneration. Mol. Neurobiol. 2008, 38:253-269.
142. Sandberg M.A., Rosner B., Weigel-DiFranco C., Berson E.L. Lack of scientific rationale for use of valproic acid for retinitis pigmentosa. Br. J. Ophthalmol. 2011, 95:744.
143. Sanvicens N., Cotter T.G. Ceramide is the key mediator of oxidative stress-induced apoptosis in retinal photoreceptor cells. J.Neurochem. 2006, 98:1432-1444.
144. Scarlatti F., Sala G., Somenzi G., Signorelli P., Sacchi N., Ghidoni R. Resveratrol induces growth inhibition and apoptosis in metastatic breast cancer cells via de novo ceramide signaling. FASEB J. 2003, 17:2339-2341.
145. Schatz A., Rock T., Naycheva L., Willmann G., Wilhelm B., Peters T., Bartz-Schmidt K.U., Zrenner E., Messias A., Gekeler F. Transcorneal electrical stimulation for patients with retinitis pigmentosa: a prospective, randomized, sham-controlled exploratory study. Investig. Ophthalmol. Vis. Sci. 2011, 52:4485-4496.
146. Shanmugam P.M., Minija C.K., Ramanjulu R., Tekwani P., Saxena M. Effect of short-term oral valproic acid on vision and visual field in retinitis pigmentosa. Ophthalmol. Ther. 2012, 1:6.
147. Shen J., Yang X., Dong A., Petters R.M., Peng Y.W., Wong F., Campochiaro P.A. Oxidative damage is a potential cause of cone cell death in retinitis pigmentosa. J.Cell. Physiol. 2005, 203:457-464.
148. Sisk R.A. Valproic acid treatment may be harmful in non-dominant forms of retinitis pigmentosa. Br. J. Ophthalmol. 2012, 96:1154-1155.
149. Spires T.L., Grote H.E., Varshney N.K., Cordery P.M., van Dellen A., Blakemore C., Hannan A.J. Environmental enrichment rescues protein deficits in a mouse model of Huntington's disease, indicating a possible disease mechanism. J.Neurosci. 2004, 24:2270-2276.
150. Srour M., Querques G., Leveziel N., Zerbib J., Tilleul J., Boulanger-Scemama E., Souied E.H. Intravitreal dexamethasone implant (Ozurdex) for macular edema secondary to retinitis pigmentosa. Graefes Arch. Clin. Exp. Ophthalmol. 2013, 251:1501-1506.
151. Stingl K., Zrenner E. Electronic approaches to restitute vision in patients with neurodegenerative diseases of the retina. Ophthalmic Res. 2013, 50:215-220.
152. Strettoi E., Gargini C., Novelli E., Sala G., Piano I., Gasco P., Ghidoni R. Inhibition of ceramide biosynthesis preserves photoreceptor structure and function in a mouse model of retinitis pigmentosa. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:18706-18711.
153. Szabadfi K., Atlasz T., Horvath G., Kiss P., Hamza L., Farkas J., Tamas A., Lubics A., Gabriel R., Reglodi D. Early postnatal enriched environment decreases retinal degeneration induced by monosodium glutamate treatment in rats. Brain Res. 2009, 1259:107-112.
154. Tanimoto N., Sothilingam V., Euler T., Ruth P., Seeliger M.W., Schubert T. BK channels mediate pathway-specific modulation of visual signals in the invivo mouse retina. J.Neurosci. 2012, 32:4861-4866.
155. Tao W., Wen R., Goddard M.B., Sherman S.D., O'Rourke P.J., Stabila P.F., Bell W.J., Dean B.J., Kauper K.A., Budz V.A., Tsiaras W.G., Acland G.M., Pearce-Kelling S., Laties A.M., Aguirre G.D. Encapsulated cell-based delivery of CNTF reduces photoreceptor degeneration in animal models of retinitis pigmentosa. Investig. Ophthalmol. Vis. Sci. 2002, 43:3292-3298.
156. Tawada A., Sugawara T., Ogata K., Hagiwara A., Yamamoto S. Improvement of central retinal sensitivity six months after topical isopropyl unoprostone in patients with retinitis pigmentosa. Indian J. Ophthalmol. 2013, 61:95-99.
157. Thanos C., Emerich D. Delivery of neurotrophic factors and therapeutic proteins for retinal diseases. Expert Opin. Biol. Ther. 2005, 5:1443-1452.
158. Thompson D.A., Ali R.R., Banin E., Branham K.E., Flannery J.G., Gamm D.M., Hauswirth W.W., Heckenlively J.R., Iannaccone A., Jayasundera K.T., Khan N.W., Molday R.S., Pennesi M.E., Reh T.A., Weleber R.G., Zacks D.N. Advancing therapeutic strategies for inherited retinal degeneration: recommendations from the Monaciano Symposium. Investig. Ophthalmol. Vis. Sci. 2015, 56:918-931.
159. Trifunovic D., Sahaboglu A., Kaur J., Mencl S., Zrenner E., Ueffing M., Arango-Gonzalez B., Paquet-Durand F. Neuroprotective strategies for the treatment of inherited photoreceptor degeneration. Curr. Mol. Med. 2012, 12:598-612.
160. Tsang S.H., Chen J., Kjeldbye H., Li W.S., Simon M.I., Gouras P., Goff S.P. Retarding photoreceptor degeneration in Pdegtm1/Pdegtml mice by an apoptosis suppressor gene. Investig. Ophthalmol. Vis. Sci. 1997, 38:943-950.
161. Tuson M., Marfany G., Gonzalez-Duarte R. Mutation of CERKL, a novel human ceramide kinase gene, causes autosomal recessive retinitis pigmentosa (RP26). Am. J. Hum. Genet. 2004, 74:128-138.
162. Usui S., Komeima K., Lee S.Y., Jo Y.J., Ueno S., Rogers B.S., Wu Z., Shen J., Lu L., Oveson B.C., Rabinovitch P.S., Campochiaro P.A. Increased expression of catalase and superoxide dismutase 2 reduces cone cell death in retinitis pigmentosa. Mol. Ther. 2009, 17:778-786.
163. Valter K., Maslim J., Bowers F., Stone J. Photoreceptor dystrophy in the RCS rat: roles of oxygen, debris, and bFGF. Investig. Ophthalmol. Vis. Sci. 1998, 39:2427-2442.
164. van Dellen A., Blakemore C., Deacon R., York D., Hannan A.J. Delaying the onset of Huntington's in mice. Nature 2000, 404:721-722.
165. van Schooneveld M.J., van den Born L.I., van Genderen M., Bollemeijer J.G. The conclusions of Clemson etal concerning valproic acid are premature. Br. J. Ophthalmol. 2011, 95:153. Author reply 153-154.
166. van Soest S., Westerveld A., de Jong P.T., Bleeker-Wagemakers E.M., Bergen A.A. Retinitis pigmentosa: defined from a molecular point of view. Surv. Ophthalmol. 1999, 43:321-334.
167. Viringipurampeer I.A., Bashar A.E., Gregory-Evans C.Y., Moritz O.L., Gregory-Evans K. Targeting inflammation in emerging therapies for genetic retinal disease. Int. J. Inflam. 2013, 2013:581751.
168. Wang C., Hou H., Nan K., Sailor M.J., Freeman W.R., Cheng L. Intravitreal controlled release of dexamethasone from engineered microparticles of porous silicon dioxide. Exp. Eye Res. 2014, 129:74-82.
169. Wang J., Deretic D. Molecular complexes that direct rhodopsin transport to primary cilia. Prog. Retin. Eye Res. 2014, 38:1-19.
170. Watson C.M., El-Asrag M., Parry D.A., Morgan J.E., Logan C.V., Carr I.M., Sheridan E., Charlton R., Johnson C.A., Taylor G., Toomes C., McKibbin M., Inglehearn C.F., Ali M. Mutation screening of retinal dystrophy patients by targeted capture from tagged pooled DNAs and next generation sequencing. PLoS One 2014, 9:e104281.
171. Weissmiller A.M., Wu C. Current advances in using neurotrophic factors to treat neurodegenerative disorders. Transl. Neurodegener. 2012, 1:14.
172. Wen R., Song Y., Kjellstrom S., Tanikawa A., Liu Y., Li Y., Zhao L., Bush R.A., Laties A.M., Sieving P.A. Regulation of rod phototransduction machinery by ciliary neurotrophic factor. J.Neurosci. 2006, 26:13523-13530.
173. Wen R., Tao W., Li Y., Sieving P.A. CNTF and retina. Prog. Retin Eye Res. 2012, 31:136-151.
174. Williamson L.L., Chao A., Bilbo S.D. Environmental enrichment alters glial antigen expression and neuroimmune function in the adult rat hippocampus. Brain Behav. Immun. 2012, 26:500-510.
175. Winter J.O., Cogan S.F., Rizzo J.F. Retinal prostheses: current challenges and future outlook. J.Biomater. Sci. Polym. Ed. 2007, 18:1031-1055.
176. Yamamoto S., Sugawara T., Murakami A., Nakazawa M., Nao I.N., Machida S., Wada Y., Mashima Y., Myake Y. Topical isopropyl unoprostone for retinitis pigmentosa: microperimetric results of the phase 2 clinical study. Ophthalmol. Ther. 2012, 1:5.
177. Yao J., Tucker B.A., Zhang X., Checa-Casalengua P., Herrero-Vanrell R., Young M.J. Robust cell integration from co-transplantation of biodegradable MMP2-PLGA microspheres with retinal progenitor cells. Biomaterials 2011, 32:1041-1050.
178. Yasukawa T., Ogura Y., Tabata Y., Kimura H., Wiedemann P., Honda Y. Drug delivery systems for vitreoretinal diseases. Prog. Retin. Eye Res. 2004, 23:253-281.
179. Yoshida N., Ikeda Y., Notomi S., Ishikawa K., Murakami Y., Hisatomi T., Enaida H., Ishibashi T. Clinical evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013, 120:100-105.
180. Yoshida N., Ikeda Y., Notomi S., Ishikawa K., Murakami Y., Hisatomi T., Enaida H., Ishibashi T. Laboratory evidence of sustained chronic inflammatory reaction in retinitis pigmentosa. Ophthalmology 2013, 120:e5-12.
181. Yu D.Y., Cringle S., Valter K., Walsh N., Lee D., Stone J. Photoreceptor death, trophic factor expression, retinal oxygen status, and photoreceptor function in the P23H rat. Investig. Ophthalmol. Vis. Sci. 2004, 45:2013-2019.
182. Yu D.Y., Cringle S.J., Su E.N., Yu P.K. Intraretinal oxygen levels before and after photoreceptor loss in the RCS rat. Investig. Ophthalmol. Vis. Sci. 2000, 41:3999-4006.
183. Zeidan Y.H., Hannun Y.A. Translational aspects of sphingolipid metabolism. Trends Mol. Med. 2007, 13:327-336.
184. Zeidan Y.H., Jenkins R.W., Korman J.B., Liu X., Obeid L.M., Norris J.S., Hannun Y.A. Molecular targeting of acid ceramidase: implications to cancer therapy. Curr. Drug Targets 2008, 9:653-661.
185. Zein W.M., Jeffrey B.G., Wiley H.E., Turriff A.E., Tumminia S.J., Tao W., Bush R.A., Marangoni D., Wen R., Wei L.L., Sieving P.A. CNGB3-achromatopsia clinical trial with CNTF: diminished rod pathway responses with no evidence of improvement in cone function. Investig. Ophthalmol. Vis. Sci. 2014, 55:6301-6308.
186. Zhang Z., Qin X., Tong N., Zhao X., Gong Y., Shi Y., Wu X. Valproic acid-mediated neuroprotection in retinal ischemia injury via histone deacetylase inhibition and transcriptional activation. Exp. Eye Res. 2012, 94:98-108.
187. Zhang Z., Qin X., Zhao X., Tong N., Gong Y., Zhang W., Wu X. Valproic acid regulates antioxidant enzymes and prevents ischemia/reperfusion injury in the rat retina. Curr. Eye Res. 2012, 37:429-437.